Skip to main
STTK
STTK logo

Shattuck Labs (STTK) Stock Forecast & Price Target

Shattuck Labs (STTK) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Shattuck Labs Inc. is strategically positioned in the biotechnology sector with its development of innovative treatments for inflammatory bowel disease (IBD), specifically through its main program SL-325, a potential first-in-class DR3 antagonist antibody. The reported increase in the use of biologics among patients with Crohn's disease (CD) from 22% to 44% and ulcerative colitis (UC) from 5% to 16% between 2007 and 2015 illustrates a growing market for biologic therapies, which could contribute to substantial demand for Shattuck Labs's products. Furthermore, the optimistic projections for market share growth, supported by a focus on strong efficacy and safety profiles, suggest solid commercial prospects for SL-325 and its extended half-life counterpart, SL-425.

Bears say

Shattuck Labs Inc. faces a negative outlook primarily due to the potential inefficacy of its lead programs, including SL-325 and SL-425, which may not meet clinical response or safety standards necessary for successful market introduction. Additionally, the consistently underestimated market growth and therapy adoption rates in inflammatory bowel disease (IBD) could lead to reduced demand for the company's products in a competitive landscape. Lastly, any significant immunogenicity issues or adverse safety signals emerging during trials could hinder product development and limit commercial uptake, further exacerbating the company's financial challenges.

Shattuck Labs (STTK) has been analyzed by 2 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Shattuck Labs (STTK) Forecast

Analysts have given Shattuck Labs (STTK) a Buy based on their latest research and market trends.

According to 2 analysts, Shattuck Labs (STTK) has a Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Shattuck Labs (STTK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.